1
|
In-situ bio-assembled specific Au NCs-Aptamer-Pyro conjugates nanoprobe for tumor imaging and mitochondria-targeted photodynamic therapy. Biosens Bioelectron 2022; 218:114763. [PMID: 36240628 DOI: 10.1016/j.bios.2022.114763] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2022] [Revised: 09/14/2022] [Accepted: 09/25/2022] [Indexed: 11/22/2022]
Abstract
Mitochondrion has emerged as a promising drug target for photodynamic therapy (PDT), due to its significant role in supporting life activities and being reactive oxygen species (ROS)-sensitive. Herein, we establish a new strategy that in-situ bio-synthesized Au NCs combine with mitochondria-targeted aptamer-Pyro conjugates (ApPCs) for specific tumor imaging and PDT. The prepared ApPCs can serve as template for the in-situ bio-synthesis of Au NCs, thereby facilitating the generation of Au NCs-ApPCs assemblies in unique tumor microenvironment. Compared with highly negatively charged ApPCs, bio-synthesized nanoscale Au NCs-ApPCs assemblies are conducive to cell uptake, which consequently benefits the delivery of ApPCs. After dissociated from Au NCs-ApPCs, internalized ApPCs can selectively accumulate in mitochondria and generate excess ROS to disrupt the mitochondrial membrane upon irradiation, thus inducing efficient cell killing. In vitro assays demonstrated that the fluorescent Au NCs-ApPCs assemblies could be specifically produced in cancerous cells, indicating the specific tumor imaging ability, while intracellular ApPCs co-localized well with mitochondria. CCK-8 results revealed over 80% cell death after PDT. In vivo study showed that fluorescent Au NCs-ApPCs assemblies were exclusively generated in tumor and achieved long-term retention; tumor growth was significantly inhibited after 15-day PDT treatment. All these evidences suggest that in-situ bio-synthesized Au NCs-ApPCs assembly is a potent mitochondria-targeted nanoprobe to boost the PDT efficacy of cancers.
Collapse
|
2
|
Gao F, Yin J, Chen Y, Guo C, Hu H, Su J. Recent advances in aptamer-based targeted drug delivery systems for cancer therapy. Front Bioeng Biotechnol 2022; 10:972933. [PMID: 36051580 PMCID: PMC9424825 DOI: 10.3389/fbioe.2022.972933] [Citation(s) in RCA: 21] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2022] [Accepted: 07/12/2022] [Indexed: 11/13/2022] Open
Abstract
The past decade has become an important strategy in precision medicine for the targeted therapy of many diseases, expecially various types of cancer. As a promising targeted element, nucleic acid aptamers are single-stranded functional oligonucleotides which have specific abilities to bind with various target molecules ranging from small molecules to entire organisms. They are often named ‘chemical antibody’ and have aroused extensive interest in diverse clinical studies on account of their advantages, such as considerable biostability, versatile chemical modification, low immunogenicity and quick tissue penetration. Thus, aptamer-embedded drug delivery systems offer an unprecedented opportunity in bioanalysis and biomedicine. In this short review, we endeavor to discuss the recent advances in aptamer-based targeted drug delivery platforms for cancer therapy. Some perspectives on the advantages, challenges and opportunities are also presented.
Collapse
Affiliation(s)
- Fei Gao
- Institude of Translation Medicine, Shanghai University, Shanghai, China
| | - Jianhui Yin
- Institude of Translation Medicine, Shanghai University, Shanghai, China
| | - Yan Chen
- Department of Pharmacy, Medical Supplies Center of PLA General Hospital, Beijing, China
| | - Changyong Guo
- Institude of Translation Medicine, Shanghai University, Shanghai, China
| | - Honggang Hu
- Institude of Translation Medicine, Shanghai University, Shanghai, China
- *Correspondence: Jiacan Su, ; Honggang Hu,
| | - Jiacan Su
- Institude of Translation Medicine, Shanghai University, Shanghai, China
- *Correspondence: Jiacan Su, ; Honggang Hu,
| |
Collapse
|
3
|
Aerssens D, Cadoni E, Tack L, Madder A. A Photosensitized Singlet Oxygen ( 1O 2) Toolbox for Bio-Organic Applications: Tailoring 1O 2 Generation for DNA and Protein Labelling, Targeting and Biosensing. MOLECULES (BASEL, SWITZERLAND) 2022; 27:molecules27030778. [PMID: 35164045 PMCID: PMC8838016 DOI: 10.3390/molecules27030778] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Revised: 01/17/2022] [Accepted: 01/18/2022] [Indexed: 12/17/2022]
Abstract
Singlet oxygen (1O2) is the excited state of ground, triplet state, molecular oxygen (O2). Photosensitized 1O2 has been extensively studied as one of the reactive oxygen species (ROS), responsible for damage of cellular components (protein, DNA, lipids). On the other hand, its generation has been exploited in organic synthesis, as well as in photodynamic therapy for the treatment of various forms of cancer. The aim of this review is to highlight the versatility of 1O2, discussing the main bioorganic applications reported over the past decades, which rely on its production. After a brief introduction on the photosensitized production of 1O2, we will describe the main aspects involving the biologically relevant damage that can accompany an uncontrolled, aspecific generation of this ROS. We then discuss in more detail a series of biological applications featuring 1O2 generation, including protein and DNA labelling, cross-linking and biosensing. Finally, we will highlight the methodologies available to tailor 1O2 generation, in order to accomplish the proposed bioorganic transformations while avoiding, at the same time, collateral damage related to an untamed production of this reactive species.
Collapse
|
4
|
Ma Z, Foda MF, Zhao Y, Han H. Multifunctional Nanosystems with Enhanced Cellular Uptake for Tumor Therapy. Adv Healthc Mater 2022; 11:e2101703. [PMID: 34626528 DOI: 10.1002/adhm.202101703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2021] [Revised: 10/01/2021] [Indexed: 11/10/2022]
Abstract
Rapid development of nanotechnology provides promising strategies in biomedicine, especially in tumor therapy. In particular, the cellular uptake of nanosystems is not only a basic premise to realize various biomedical applications, but also a fatal factor for determining the final therapeutic effect. Thus, a systematic and comprehensive summary is necessary to overview the recent research progress on the improvement of nanosystem cellular uptake for cancer treatment. According to the process of nanosystems entering the body, they can be classified into three categories. The first segment is to enhance the accumulation and permeation of nanosystems to tumor cells through extracellular microenvironment stimulation. The second segment is to improve cellular internalization from extracellular to intracellular via active targeting. The third segment is to enhance the intracellular retention of therapeutics by subcellular localization. The major factors in the delivery can be utilized to develop multifunctional nanosystems for strengthening the tumor therapy. Ultimately, the key challenges and prospective in the emerging research frontier are thoroughly outlined. This review is expected to provide inspiring ideas, promising strategies and potential pathways for developing advanced anticancer nanosystems in clinical practice.
Collapse
Affiliation(s)
- Zhaoyu Ma
- State Key Laboratory of Agricultural Microbiology College of Life Science and Technology Huazhong Agricultural University Wuhan Hubei 430070 P. R. China
- Division of Chemistry and Biological Chemistry School of Physical and Mathematical Sciences Nanyang Technological University 21 Nanyang Link Singapore 637371 Singapore
| | - Mohamed F. Foda
- State Key Laboratory of Agricultural Microbiology College of Life Science and Technology Huazhong Agricultural University Wuhan Hubei 430070 P. R. China
- Department of Biochemistry Faculty of Agriculture Benha University Moshtohor Toukh 13736 Egypt
| | - Yanli Zhao
- State Key Laboratory of Agricultural Microbiology College of Life Science and Technology Huazhong Agricultural University Wuhan Hubei 430070 P. R. China
- Division of Chemistry and Biological Chemistry School of Physical and Mathematical Sciences Nanyang Technological University 21 Nanyang Link Singapore 637371 Singapore
| | - Heyou Han
- State Key Laboratory of Agricultural Microbiology College of Life Science and Technology Huazhong Agricultural University Wuhan Hubei 430070 P. R. China
| |
Collapse
|
5
|
Yan J, Gao T, Lu Z, Yin J, Zhang Y, Pei R. Aptamer-Targeted Photodynamic Platforms for Tumor Therapy. ACS APPLIED MATERIALS & INTERFACES 2021; 13:27749-27773. [PMID: 34110790 DOI: 10.1021/acsami.1c06818] [Citation(s) in RCA: 40] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Achieving controlled and accurate delivery of photosensitizers (PSs) into tumor sites is a major challenge in conventional photodynamic therapy (PDT). Aptamer is a short oligonucleotide sequence (DNA or RNA) with a folded three-dimensional structure, which can selectively bind to specific small molecules, proteins, or the whole cells. Aptamers could act as ligands and be modified onto PSs or nanocarriers, enabling specific recognition and binding to tumor cells or their membrane proteins. The resultant aptamer-modified PSs or PSs-containing nanocarriers generate amounts of reactive oxygen species with light irradiation and obtain superior photodynamic therapeutic efficiency in tumors. Herein, we overview the recent progress in the designs and applications of aptamer-targeted photodynamic platforms for tumor therapy. First, we focus on the progress on the rational selection of aptamers and summarize the applications of aptamers which have been applied for targeted tumor diagnosis and therapy. Then, aptamer-targeted photodynamic therapies including various aptamer-PSs, aptamer-nanocarriers containing PSs, and aptamer-nano-photosensitizers are highlighted. The aptamer-targeted synergistically therapeutic platforms including PDT, photothermal therapy, and chemotherapy, as well as the imaging-guided theranostics, are also discussed. Finally, we offer an insight into the development trends and future perspectives of aptamer-targeted photodynamic platforms for tumor therapy.
Collapse
Affiliation(s)
- Jincong Yan
- Department of Polymer Materials, School of Materials Science and Engineering, Shanghai University, 200444 Shanghai, China
- CAS Key Laboratory for Nano-Bio Interface, Suzhou Institute of Nano-tech and Nano-bionics, Chinese Academy of Sciences, 215123 Suzhou, China
| | - Tian Gao
- CAS Key Laboratory for Nano-Bio Interface, Suzhou Institute of Nano-tech and Nano-bionics, Chinese Academy of Sciences, 215123 Suzhou, China
| | - Zhongzhong Lu
- CAS Key Laboratory for Nano-Bio Interface, Suzhou Institute of Nano-tech and Nano-bionics, Chinese Academy of Sciences, 215123 Suzhou, China
| | - Jingbo Yin
- Department of Polymer Materials, School of Materials Science and Engineering, Shanghai University, 200444 Shanghai, China
| | - Ye Zhang
- CAS Key Laboratory for Nano-Bio Interface, Suzhou Institute of Nano-tech and Nano-bionics, Chinese Academy of Sciences, 215123 Suzhou, China
| | - Renjun Pei
- CAS Key Laboratory for Nano-Bio Interface, Suzhou Institute of Nano-tech and Nano-bionics, Chinese Academy of Sciences, 215123 Suzhou, China
| |
Collapse
|
6
|
Ando T, Yamamoto M, Takamori Y, Tsukamoto K, Fuji D, Kawakami T. In vitro selection of an RNA aptamer yields an interleukin-6/interleukin-6 receptor interaction inhibitor. Biosci Biotechnol Biochem 2021; 85:1170-1174. [PMID: 33590853 PMCID: PMC7799299 DOI: 10.1093/bbb/zbaa124] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2020] [Accepted: 12/29/2020] [Indexed: 12/13/2022]
Abstract
Interleukin-6 (IL-6) binds to IL-6 receptor (IL-6R) subunit, related to autoimmune diseases and cytokine storm in COVID-19. In this study we performed Systematic Evolution of Ligands by Exponential enrichment (SELEX) and identified a novel RNA aptamer. This RNA aptamer not only bound to IL-6R with a dissociation constant of 200 nM, but also inhibited the interaction of IL-6R with IL-6.
Collapse
Affiliation(s)
- Takehiro Ando
- Department of Life and Environmental Sciences, Integrated Graduate School of Medicine, Engineering, and Agricultural Sciences, University of Yamanashi, Kofu, Yamanashi, Japan
| | - Mizuki Yamamoto
- Department of Integrated Applied Life Science, Integrated Graduate School of Medicine, Engineering, and Agricultural Sciences, University of Yamanashi, Kofu, Yamanashi, Japan
| | - Yukio Takamori
- Department of Life and Environmental Sciences, Integrated Graduate School of Medicine, Engineering, and Agricultural Sciences, University of Yamanashi, Kofu, Yamanashi, Japan
| | - Keita Tsukamoto
- Department of Life and Environmental Sciences, Integrated Graduate School of Medicine, Engineering, and Agricultural Sciences, University of Yamanashi, Kofu, Yamanashi, Japan
| | - Daisuke Fuji
- Department of Biotechnology, Faculty of Life and Environmental Sciences, University of Yamanashi, Kofu, Yamanashi, Japan
| | - Takashi Kawakami
- Faculty of Life and Environmental Sciences, Graduate Faculty of Interdisciplinary Research, University of Yamanashi, Kofu, Yamanashi, Japan.,JST, PRESTO, Kawaguchi, Saitama, Japan
| |
Collapse
|
7
|
Takamori Y, Ando T, Fuji D, Yokoyama T, Yamamoto M, Kawakami T. In vitro display evolution of IL-6R-binding unnatural peptides ribosomally initiated and cyclized with m-(chloromethyl)benzoic acid. Biochem Biophys Res Commun 2020; 535:47-53. [PMID: 33340765 DOI: 10.1016/j.bbrc.2020.11.123] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2020] [Accepted: 11/30/2020] [Indexed: 11/26/2022]
Abstract
The interaction of the multifunctional cytokine interleukin (IL)-6 and its receptor (IL-6R) is involved in various diseases, including not only autoimmune diseases such as rheumatoid arthritis but also cancer and cytokine storms in coronavirus disease 2019 (COVID-19). In this study, systematic evolution of ligands by exponential enrichment (SELEX) against human IL-6R from mRNA-displayed unnatural peptide library ribosomally initiated and cyclized with m-(chloromethyl)benzoic acid (mClPh) incorporated by genetic code expansion (sense suppression) was performed using the PURE (Protein synthesis Using Recombinant Elements) system. A novel 13-mer unnatural mClPh-cyclized peptide that binds to the extracellular domain of IL-6R was discovered from an extremely diverse random peptide library. In vitro affinity maturation of IL-6R-binding unnatural mClPh-cyclized peptide from focused libraries was performed, identifying two IL-6R-binding unnatural mClPh-cyclized peptides by next-generation sequencing. Because cyclization can increase the protease resistance of peptides, novel IL-6R-binding mClPh-cyclized peptides discovered in this study have the potential to be used for a variety of research, therapeutic, and diagnostic applications involving IL-6/IL-6R signaling.
Collapse
Affiliation(s)
- Yukio Takamori
- Department of Life and Environmental Sciences, Integrated Graduate School of Medicine, Engineering and Agricultural Sciences, University of Yamanashi, 4-4-37 Takeda, Kofu, Yamanashi, 400-8510, Japan
| | - Takehiro Ando
- Department of Life and Environmental Sciences, Integrated Graduate School of Medicine, Engineering and Agricultural Sciences, University of Yamanashi, 4-4-37 Takeda, Kofu, Yamanashi, 400-8510, Japan
| | - Daisuke Fuji
- Department of Biotechnology, Faculty of Life and Environmental Sciences, University of Yamanashi, 4-4-37 Takeda, Kofu, Yamanashi, 400-8510, Japan
| | - Takumi Yokoyama
- Department of Life and Environmental Sciences, Integrated Graduate School of Medicine, Engineering and Agricultural Sciences, University of Yamanashi, 4-4-37 Takeda, Kofu, Yamanashi, 400-8510, Japan
| | - Mizuki Yamamoto
- Department of Integrated Applied Life Science, Integrated Graduate School of Medicine, Engineering, and Agricultural Sciences, University of Yamanashi, 4-4-37 Takeda, Kofu, Yamanashi, 400-8510, Japan
| | - Takashi Kawakami
- Faculty of Life and Environmental Sciences, Graduate Faculty of Interdisciplinary Research, University of Yamanashi, 4-4-37 Takeda, Kofu, Yamanashi, 400-8510, Japan; JST, PRESTO, 4-1-8 Honcho, Kawaguchi, Saitama, 332-0012, Japan.
| |
Collapse
|
8
|
A hybrid biomaterial of biosilica and C-phycocyanin for enhanced photodynamic effect towards tumor cells. Biochem Biophys Res Commun 2020; 533:573-579. [PMID: 32981676 DOI: 10.1016/j.bbrc.2020.09.049] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2020] [Accepted: 09/14/2020] [Indexed: 11/20/2022]
Abstract
Intricate mesoporous biosilica has many biomedical applications as a nanocarrier. However, its potential use in photodynamic therapy (PDT) has received little attention. This work reports the first fabrication of bio-engineered materials by covalently conjugating C-phycocyanin (C-PC), a natural photosensitizer, to biosilica for the PDT of tumor-associated macrophages. The resulting hybrid material showed outstanding photodynamic activity under 620 nm laser irradiation. Furthermore, it enhanced the relatively weak photodynamic effect of C-PC. This study also explored methods of biofunctionalizing biosilica for cancer phototherapy, a new pharmacological application of non-toxic C-PC.
Collapse
|
9
|
Shatunova EA, Korolev MA, Omelchenko VO, Kurochkina YD, Davydova AS, Venyaminova AG, Vorobyeva MA. Aptamers for Proteins Associated with Rheumatic Diseases: Progress, Challenges, and Prospects of Diagnostic and Therapeutic Applications. Biomedicines 2020; 8:biomedicines8110527. [PMID: 33266394 PMCID: PMC7700471 DOI: 10.3390/biomedicines8110527] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2020] [Revised: 11/18/2020] [Accepted: 11/20/2020] [Indexed: 02/07/2023] Open
Abstract
Nucleic acid aptamers capable of affine and specific binding to their molecular targets have now established themselves as a very promising alternative to monoclonal antibodies for diagnostic and therapeutic applications. Although the main focus in aptamers’ research and development for biomedicine is made on cardiovascular, infectious, and malignant diseases, the use of aptamers as therapeutic or diagnostic tools in the context of rheumatic diseases is no less important. In this review, we consider the main features of aptamers that make them valuable molecular tools for rheumatologists, and summarize the studies on the selection and application of aptamers for protein biomarkers associated with rheumatic diseases. We discuss the progress in the development of aptamer-based diagnostic assays and targeted therapeutics for rheumatic disorders, future prospects in the field, and issues that have yet to be addressed.
Collapse
Affiliation(s)
- Elizaveta A. Shatunova
- Institute of Chemical Biology and Fundamental Medicine, Siberian Division of Russian Academy of Sciences, 630090 Novosibirsk, Russia; (E.A.S.); (A.S.D.); (A.G.V.)
| | - Maksim A. Korolev
- Research Institute of Clinical and Experimental Lymphology, Affiliated Branch of Federal Research Center of Cytology and Genetics, Siberian Division of the Russian Academy of Sciences, 630060 Novosibirsk, Russia; (M.A.K.); (V.O.O.); (Y.D.K.)
| | - Vitaly O. Omelchenko
- Research Institute of Clinical and Experimental Lymphology, Affiliated Branch of Federal Research Center of Cytology and Genetics, Siberian Division of the Russian Academy of Sciences, 630060 Novosibirsk, Russia; (M.A.K.); (V.O.O.); (Y.D.K.)
| | - Yuliya D. Kurochkina
- Research Institute of Clinical and Experimental Lymphology, Affiliated Branch of Federal Research Center of Cytology and Genetics, Siberian Division of the Russian Academy of Sciences, 630060 Novosibirsk, Russia; (M.A.K.); (V.O.O.); (Y.D.K.)
| | - Anna S. Davydova
- Institute of Chemical Biology and Fundamental Medicine, Siberian Division of Russian Academy of Sciences, 630090 Novosibirsk, Russia; (E.A.S.); (A.S.D.); (A.G.V.)
| | - Alya G. Venyaminova
- Institute of Chemical Biology and Fundamental Medicine, Siberian Division of Russian Academy of Sciences, 630090 Novosibirsk, Russia; (E.A.S.); (A.S.D.); (A.G.V.)
| | - Mariya A. Vorobyeva
- Institute of Chemical Biology and Fundamental Medicine, Siberian Division of Russian Academy of Sciences, 630090 Novosibirsk, Russia; (E.A.S.); (A.S.D.); (A.G.V.)
- Correspondence:
| |
Collapse
|
10
|
Gierlich P, Mata AI, Donohoe C, Brito RMM, Senge MO, Gomes-da-Silva LC. Ligand-Targeted Delivery of Photosensitizers for Cancer Treatment. Molecules 2020; 25:E5317. [PMID: 33202648 PMCID: PMC7698280 DOI: 10.3390/molecules25225317] [Citation(s) in RCA: 42] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2020] [Revised: 10/26/2020] [Accepted: 11/06/2020] [Indexed: 12/12/2022] Open
Abstract
Photodynamic therapy (PDT) is a promising cancer treatment which involves a photosensitizer (PS), light at a specific wavelength for PS activation and oxygen, which combine to elicit cell death. While the illumination required to activate a PS imparts a certain amount of selectivity to PDT treatments, poor tumor accumulation and cell internalization are still inherent properties of most intravenously administered PSs. As a result, common consequences of PDT include skin photosensitivity. To overcome the mentioned issues, PSs may be tailored to specifically target overexpressed biomarkers of tumors. This active targeting can be achieved by direct conjugation of the PS to a ligand with enhanced affinity for a target overexpressed on cancer cells and/or other cells of the tumor microenvironment. Alternatively, PSs may be incorporated into ligand-targeted nanocarriers, which may also encompass multi-functionalities, including diagnosis and therapy. In this review, we highlight the major advances in active targeting of PSs, either by means of ligand-derived bioconjugates or by exploiting ligand-targeting nanocarriers.
Collapse
Affiliation(s)
- Piotr Gierlich
- CQC, Coimbra Chemistry Center, Department of Chemistry, University of Coimbra, 3000-435 Coimbra, Portugal; (P.G.); (A.I.M.); (C.D.); (R.M.M.B.)
- Medicinal Chemistry, Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, Trinity College Dublin, The University of Dublin, St. James’s Hospital, D08W9RT Dublin, Ireland;
| | - Ana I. Mata
- CQC, Coimbra Chemistry Center, Department of Chemistry, University of Coimbra, 3000-435 Coimbra, Portugal; (P.G.); (A.I.M.); (C.D.); (R.M.M.B.)
| | - Claire Donohoe
- CQC, Coimbra Chemistry Center, Department of Chemistry, University of Coimbra, 3000-435 Coimbra, Portugal; (P.G.); (A.I.M.); (C.D.); (R.M.M.B.)
- Medicinal Chemistry, Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, Trinity College Dublin, The University of Dublin, St. James’s Hospital, D08W9RT Dublin, Ireland;
| | - Rui M. M. Brito
- CQC, Coimbra Chemistry Center, Department of Chemistry, University of Coimbra, 3000-435 Coimbra, Portugal; (P.G.); (A.I.M.); (C.D.); (R.M.M.B.)
- BSIM Therapeutics, Instituto Pedro Nunes, 3030-199 Coimbra, Portugal
| | - Mathias O. Senge
- Medicinal Chemistry, Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, Trinity College Dublin, The University of Dublin, St. James’s Hospital, D08W9RT Dublin, Ireland;
| | - Lígia C. Gomes-da-Silva
- CQC, Coimbra Chemistry Center, Department of Chemistry, University of Coimbra, 3000-435 Coimbra, Portugal; (P.G.); (A.I.M.); (C.D.); (R.M.M.B.)
| |
Collapse
|
11
|
Wang C, Chen P, Qiao Y, Kang Y, Yan C, Yu Z, Wang J, He X, Wu H. pH responsive superporogen combined with PDT based on poly Ce6 ionic liquid grafted on SiO 2 for combating MRSA biofilm infection. Theranostics 2020; 10:4795-4808. [PMID: 32308750 PMCID: PMC7163436 DOI: 10.7150/thno.42922] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2019] [Accepted: 03/05/2020] [Indexed: 02/07/2023] Open
Abstract
Background: Biofilm infection caused by multidrug-resistant bacteria is difficult to eradicate by conventional therapies. Photodynamic therapy (PDT) is an effective antibacterial method for fighting against biofilm infection. However, the blocked photosensitizers outside of biofilm greatly limit the efficacy of PDT. Methods: Herein, a novel acid-responsive superporogen and photosensitizer (SiO2-PCe6-IL) was developed. Because of the protonation of the photosensitizer and the high binding energy of the polyionic liquid, SiO2-PCe6-IL changed to positive SiO2-PIL+ in an acidic microenvironment of biofilm infection. SiO2-PIL+ could combine with negatively charged extracellular polymeric substances (EPS) and create holes to remove the biofilm barrier. To strengthen the interaction between SiO2-PIL+ and EPS, SiO2-PIL+ of high charge density was prepared by grafting the high-density initiation site of ATRP onto the surface of the SiO2 base. Results: Due to the rapid protonation rate of COO- and the strong binding energy of SiO2-PIL+ with EPS, SiO2-PCe6-IL could release 90% of Ce6 in 10 s. With the stronger electrostatic and hydrophobic interaction of SiO2-PIL+ with EPS, the surface potential, hydrophobicity, adhesion and mechanical strength of biofilm were changed, and holes in the biofilm were created in 10 min. Combining with the release of photosensitizers and the porous structure of the biofilm, Ce6 was efficiently concentrated in the biofilm. The in vitro and in vivo antibacterial experiments proved that SiO2-PCe6-IL dramatically improved the PDT efficacy against MRSA biofilm infection. Conclusion: These findings suggest that SiO2-PCe6-IL could rapidly increase the concentration of photosensitizer in biofilm and it is an effective therapy for combating biofilm infection.
Collapse
|
12
|
Poiroux G, Barre A, Rougé P, Benoist H. Targeting Glycosylation Aberrations to Improve the Efficiency of Cancer Phototherapy. Curr Cancer Drug Targets 2019; 19:349-359. [DOI: 10.2174/1568009618666180628101059] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2018] [Revised: 05/12/2018] [Accepted: 06/01/2018] [Indexed: 12/13/2022]
Abstract
The use of photodynamic therapy in cancer still remains limited, partly because of the lack of photosensitizer (PS) specificity for the cancerous tissues. Various molecular tools are available to increase PS efficiency by targeting the cancer cell molecular alterations. Most strategies use the protein-protein interactions, e.g. monoclonal antibodies directed toward tumor antigens, such as HER2 or EGFR. An alternative could be the targeting of the tumor glycosylation aberrations, e.g. T/Tn antigens that are truncated O-glycans over-expressed in numerous tumors. Thus, to achieve an effective targeting, PS can be conjugated to molecules that specifically recognize the Oglycosylation aberrations at the cancer cell surface.
Collapse
Affiliation(s)
- Guillaume Poiroux
- Universite de Toulouse, CRCT, INSERM UMR 1037, 2 Avenue Hubert Curien, 31037 Toulouse, France
| | - Annick Barre
- Universite de Toulouse, Pharma-Dev, Institut de Recherche pour le Developpement (IRD) UMR 152, Faculte des Sciences Pharmaceutiques, F-31062 Toulouse, Cedex 09, France
| | - Pierre Rougé
- Universite de Toulouse, Pharma-Dev, Institut de Recherche pour le Developpement (IRD) UMR 152, Faculte des Sciences Pharmaceutiques, F-31062 Toulouse, Cedex 09, France
| | - Hervé Benoist
- Universite de Toulouse, Pharma-Dev, Institut de Recherche pour le Developpement (IRD) UMR 152, Faculte des Sciences Pharmaceutiques, F-31062 Toulouse, Cedex 09, France
| |
Collapse
|
13
|
Prisner L, Witthöft P, Nguyen LVN, Tsangas T, Gefken T, Klaus F, Strelow C, Kipp T, Mews A. Monitoring the death of single BaF3 cells under plasmonic photothermal heating induced by ultrasmall gold nanorods. J Mater Chem B 2019. [DOI: 10.1039/c8tb03135e] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Morphological changes and trypan-blue staining are temporally tracked in single cells via optical microscopy after plasmonic photothermal heating.
Collapse
Affiliation(s)
- Lisa Prisner
- Institute of Physical Chemistry
- University of Hamburg
- D-20146, Hamburg
- Germany
| | - Phillip Witthöft
- Institute of Physical Chemistry
- University of Hamburg
- D-20146, Hamburg
- Germany
| | - Lan Vi Ngoc Nguyen
- Institute of Physical Chemistry
- University of Hamburg
- D-20146, Hamburg
- Germany
| | - Thomas Tsangas
- Institute of Physical Chemistry
- University of Hamburg
- D-20146, Hamburg
- Germany
| | - Tobias Gefken
- Institute of Physical Chemistry
- University of Hamburg
- D-20146, Hamburg
- Germany
| | - Florentine Klaus
- Institute of Physical Chemistry
- University of Hamburg
- D-20146, Hamburg
- Germany
| | - Christian Strelow
- Institute of Physical Chemistry
- University of Hamburg
- D-20146, Hamburg
- Germany
| | - Tobias Kipp
- Institute of Physical Chemistry
- University of Hamburg
- D-20146, Hamburg
- Germany
| | - Alf Mews
- Institute of Physical Chemistry
- University of Hamburg
- D-20146, Hamburg
- Germany
| |
Collapse
|
14
|
Mutas M, Strelow C, Kipp T, Mews A. Specific binding and internalization: an investigation of fluorescent aptamer-gold nanoclusters and cells with fluorescence lifetime imaging microscopy. NANOSCALE 2018; 10:20453-20461. [PMID: 30379177 DOI: 10.1039/c8nr06639f] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Fluorescent gold nanoclusters show promising properties for biological applications. We biofunctionalized fluorescent 11-mercaptoundecanoic-acid stabilized gold nanoclusters (AuNCs) with an aptamer to target the interleukin-6-receptor expressed on BaF3 cells specifically. Although the fluorescence emission of the AuNCs (535 nm) is in the same wavelength region as the autofluorescence of the cell, we are able to distinguish between nanoclusters and cells using the fluorescence decay time, which is much longer for the AuNCs (100 ns) than for the autofluorescence. After a first short incubation period we detected AuNCs specifically bound to the cell membrane by using two fluorescence lifetime imaging microscopy (FLIM) methods: gated and direct FLIM. After a second incubation period the previously bound AuNCs are internalized by the cells, as could be resolved solely by the direct FLIM. This proves the superior sensitivity of this method compared to gated FLIM. We find that the optical properties of AuNCs do not change upon binding to the cells, but exhibit a change when internalized into the cells, induced by an interaction between the AuNCs and cells.
Collapse
Affiliation(s)
- Marina Mutas
- Institute of Physical Chemistry, University of Hamburg, Grindelallee 117, Hamburg, Germany.
| | | | | | | |
Collapse
|
15
|
Zhu G, Chen X. Aptamer-based targeted therapy. Adv Drug Deliv Rev 2018; 134:65-78. [PMID: 30125604 PMCID: PMC6239901 DOI: 10.1016/j.addr.2018.08.005] [Citation(s) in RCA: 264] [Impact Index Per Article: 44.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2018] [Revised: 07/12/2018] [Accepted: 08/16/2018] [Indexed: 12/13/2022]
Abstract
Precision medicine holds great promise to harness genetic and epigenetic cues for targeted treatment of a variety of diseases, ranging from many types of cancers, neurodegenerative diseases, to cardiovascular diseases. The proteomic profiles resulting from the unique genetic and epigenetic signatures represent a class of relatively well accessible molecular targets for both interrogation (e.g., diagnosis, prognosis) and intervention (e.g., targeted therapy) of these diseases. Aptamers are promising for such applications by specific binding with cognate disease biomarkers. Nucleic acid aptamers are a class of DNA or RNA with unique three-dimensional conformations that allow them to specifically bind with target molecules. Aptamers can be relatively easily screened, reproducibly manufactured, programmably designed, and chemically modified for various biomedical applications, including targeted therapy. Aptamers can be chemically modified to resist enzymatic degradation or optimize their pharmacological behaviors, which ensured their chemical integrity and bioavailability under physiological conditions. In this review, we will focus on recent progress and discuss the challenges and opportunities in the research areas of aptamer-based targeted therapy in the forms of aptamer therapeutics and aptamer-drug conjugates (ApDCs).
Collapse
Affiliation(s)
- Guizhi Zhu
- Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298, USA
| | - Xiaoyuan Chen
- Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20892, USA.
| |
Collapse
|
16
|
Juan-Rivera MC, Martínez-Ferrer M. Integrin Inhibitors in Prostate Cancer. Cancers (Basel) 2018; 10:cancers10020044. [PMID: 29415418 PMCID: PMC5836076 DOI: 10.3390/cancers10020044] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2017] [Revised: 01/12/2018] [Accepted: 01/19/2018] [Indexed: 01/20/2023] Open
Abstract
Prostate cancer (PCa) is the most frequently diagnosed cancer and the third highest cause of cancer-related deaths in men in the U.S. The development of chemotherapeutic agents that can bind PCa tumor cells with high specificity is critical in order to increase treatment effectiveness. Integrin receptors and their corresponding ligands have different expression patterns in PCa cells. They have been identified as promising targets to inhibit pathways involved in PCa progression. Currently, several compounds have proven to target specific integrins and their subunits in PCa cells. In this article, we review the role of integrins inhibitors in PCa and their potential as therapeutic targets for PCa treatments. We have discussed the following: natural compounds, monoclonal antibodies, statins, campothecins analog, aptamers, d-aminoacid, and snake venom. Recent studies have shown that their mechanisms of action result in decrease cell migration, cell invasion, cell proliferation, and metastasis of PCa cells.
Collapse
Affiliation(s)
- Maylein C Juan-Rivera
- Department of Pharmaceutical Sciences, School of Pharmacy, University of Puerto Rico, Medical Sciences Campus, San Juan, PR 00936, USA.
- University of Puerto Rico Comprehensive Cancer Center, Medical Sciences Campus, San Juan, PR 00936, USA.
| | - Magaly Martínez-Ferrer
- Department of Pharmaceutical Sciences, School of Pharmacy, University of Puerto Rico, Medical Sciences Campus, San Juan, PR 00936, USA.
- University of Puerto Rico Comprehensive Cancer Center, Medical Sciences Campus, San Juan, PR 00936, USA.
| |
Collapse
|
17
|
Hahn U. Charomers-Interleukin-6 Receptor Specific Aptamers for Cellular Internalization and Targeted Drug Delivery. Int J Mol Sci 2017; 18:ijms18122641. [PMID: 29211023 PMCID: PMC5751244 DOI: 10.3390/ijms18122641] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2017] [Revised: 11/24/2017] [Accepted: 11/24/2017] [Indexed: 02/06/2023] Open
Abstract
Interleukin-6 (IL-6) is a key player in inflammation and the main factor for the induction of acute phase protein biosynthesis. Further to its central role in many aspects of the immune system, IL-6 regulates a variety of homeostatic processes. To interfere with IL-6 dependent diseases, such as various autoimmune diseases or certain cancers like multiple myeloma or hepatocellular carcinoma associated with chronic inflammation, it might be a sensible strategy to target human IL-6 receptor (hIL-6R) presenting cells with aptamers. We therefore have selected and characterized different DNA and RNA aptamers specifically binding IL-6R. These IL-6R aptamers, however, do not interfere with the IL-6 signaling pathway but are internalized with the receptor and thus can serve as vehicles for the delivery of different cargo molecules like therapeutics. We succeeded in the construction of a chlorin e6 derivatized aptamer to be delivered for targeted photodynamic therapy (PDT). Furthermore, we were able to synthesize an aptamer intrinsically comprising the cytostatic 5-Fluoro-2′-deoxy-uridine for targeted chemotherapy. The α6β4 integrin specific DNA aptamer IDA, also selected in our laboratory is internalized, too. All these aptamers can serve as vehicles for targeted drug delivery into cells. We call them charomers—in memory of Charon, the ferryman in Greek mythology, who ferried the deceased into the underworld.
Collapse
Affiliation(s)
- Ulrich Hahn
- Chemistry Department, Institute for Biochemistry and Molecular Biology, MIN-Faculty, Universität Hamburg, Martin-Luther-King-Platz 6, D-20146 Hamburg, Germany.
| |
Collapse
|
18
|
Singh S, Jha P, Singh V, Sinha K, Hussain S, Singh MK, Das P. A quantum dot-MUC1 aptamer conjugate for targeted delivery of protoporphyrin IX and specific photokilling of cancer cells through ROS generation. Integr Biol (Camb) 2017; 8:1040-1048. [PMID: 27723851 DOI: 10.1039/c6ib00092d] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Non-targeted photosensitizers lack selectivity that undermines the potential use of photodynamic therapy (PDT). Herein, we report the DNA mediated assembly of a ZnSe/ZnS quantum dot (QD)-photosensitizer (PS)-Mucin 1(MUC1) aptamer conjugate for targeting the MUC1 cancer biomarker and simultaneous generation of reactive oxygen species (ROS). A photosensitizer, protoporphyrin IX (PpIX), was conjugated to a single stranded DNA and self-assembled to a complementary strand that was conjugated to a QD and harboring a MUC1 aptamer sequence. A multistep fluorescence resonance energy transfer (FRET) is shown that involves the QD, PpIX and covalently linked CF™ 633 amine dye (CF dye) to the MUC1 peptide that tracks the potency of the aptamer to attach itself with the MUC1 peptide. Since the absorption spectra of the CF dye overlap with the emission spectra of PpIX, the former acts as an acceptor to PpIX forming a second FRET pair when the dye labeled MUC1 binds to the aptamer. The binding of the QD-PpIX nanoassemblies with MUC1 through the aptamer was further confirmed by gel electrophoresis and circular dichroism studies. The selective photodamage of MUC1 expressing HeLa cervical cancer cells through ROS generation in the presence of the QD-PpIX FRET probe upon irradiation is successfully demonstrated.
Collapse
Affiliation(s)
- Seema Singh
- Department of Chemistry, Indian Institute of Technology Patna, Patna 801103, Bihar, India.
| | - Pravin Jha
- Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Hajipur 844101, Bihar, India
| | - Vandana Singh
- Department of Chemistry, Indian Institute of Technology Patna, Patna 801103, Bihar, India.
| | - Kislay Sinha
- Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Hajipur 844101, Bihar, India
| | - Sahid Hussain
- Department of Chemistry, Indian Institute of Technology Patna, Patna 801103, Bihar, India.
| | - Manoj K Singh
- Atomic and Molecular Physics Division, Bhabha Atomic Research Centre, Mumbai 400085, India.
| | - Prolay Das
- Department of Chemistry, Indian Institute of Technology Patna, Patna 801103, Bihar, India.
| |
Collapse
|
19
|
SDA and IDA - Two aptamers to inhibit cancer cell adhesion. Biochimie 2017; 145:84-90. [PMID: 29080832 DOI: 10.1016/j.biochi.2017.10.018] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2017] [Accepted: 10/24/2017] [Indexed: 02/07/2023]
Abstract
Aptamers which bind to proteins involved in cell-cell interactions could have significant value to directly affect cancer cell adhesion or for directed cargo delivery. Here, I discuss two aptamers: aptamer SDA which binds to E- and P-selectin, and aptamer IDA which binds to α6β4 integrin. Both aptamers (SDA 91 nt and IDA 77 nt) bind their target proteins with dissociation constants in the 100-150 nM range and substantially inhibit special cellular adhesion, possibly a first and pivotal step in transendothelial migration during metastasis formation. The aptamers' half-lives in cell culture media are between two and six hours. IDA is internalized by integrin presenting cells within minutes thus possibly serving as vehicle for directed cargo delivery.
Collapse
|
20
|
Prisner L, Bohn N, Hahn U, Mews A. Size dependent targeted delivery of gold nanoparticles modified with the IL-6R-specific aptamer AIR-3A to IL-6R-carrying cells. NANOSCALE 2017; 9:14486-14498. [PMID: 28929152 DOI: 10.1039/c7nr02973j] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
The delivery of gold nanoparticles (AuNPs) to specific cells strongly depends on the properties e.g. the size of the particles and is of great interest for a large variety of biomedical applications. Here we investigated the size dependence of the receptor-ligand mediated AuNP delivery to cells by comparing very small "molecular" Au-clusters of only 2 nm to larger 7 nm and 36 nm AuNPs with a distinct surface plasmon resonance. Since the molecular weight in this range changes by almost three orders of magnitude, we show how the amount of gold relates to the number of delivered AuNPs. We attached small interleukin-6 receptor (IL-6R) specific aptamer molecules (AIR-3A) in different amounts to the particles and investigated the specificity of the delivery to IL-6R-carrying cells. To reduce unspecific interaction the particles were additionally covered with polyethylene glycol (PEG). Besides particle size and concentration we varied additional parameters such as aptamer surface coverage as well as incubation time and temperature. We found that in particular, small particles with diameters of less than 2 nm show an up to six times higher delivery rate for the aptamer-conjugated AuNPs compared to untargeted PEG-coated AuNPs. The specificity reduces with a decreasing aptamer/PEG ratio, and also with an increase in particle size where the unspecific uptake is much higher. In addition we also compared the delivery efficiency of this aptamer-mediated delivery system with an antibody-mediated system targeting the same receptor to validate the performance of this approach.
Collapse
Affiliation(s)
- Lisa Prisner
- Universität Hamburg, Institute for Physical Chemistry, Grindelallee 117, 20146 Hamburg, Germany.
| | | | | | | |
Collapse
|
21
|
Protti S, Albini A, Viswanathan R, Greer A. Targeting Photochemical Scalpels or Lancets in the Photodynamic Therapy Field—The Photochemist's Role. Photochem Photobiol 2017; 93:1139-1153. [DOI: 10.1111/php.12766] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2017] [Accepted: 02/20/2017] [Indexed: 01/02/2023]
Affiliation(s)
- Stefano Protti
- PhotoGreen Lab Department of Chemistry University of Pavia Pavia Italy
| | - Angelo Albini
- PhotoGreen Lab Department of Chemistry University of Pavia Pavia Italy
| | | | - Alexander Greer
- Department of Chemistry Brooklyn College Brooklyn NY
- Ph.D. Program in Chemistry The Graduate Center of the City University of New York New York City NY
| |
Collapse
|
22
|
Zhang D, Zheng A, Li J, Wu M, Cai Z, Wu L, Wei Z, Yang H, Liu X, Liu J. Tumor Microenvironment Activable Self-Assembled DNA Hybrids for pH and Redox Dual-Responsive Chemotherapy/PDT Treatment of Hepatocellular Carcinoma. ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) 2017; 4:1600460. [PMID: 28435778 PMCID: PMC5396159 DOI: 10.1002/advs.201600460] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/18/2016] [Revised: 11/25/2016] [Indexed: 05/22/2023]
Abstract
Smart self-assembled "Turn-ON" DNA hybrids are employed, which could respond to tumor microenvironment stimuli for cancer cell specific real-time fluorescence imaging, tumor-specific synergistic photodynamic therapy and chemotherapy in hepatocellular carcinoma.
Collapse
Affiliation(s)
- Da Zhang
- The Liver Center of Fujian ProvinceFujian Medical UniversityFuzhou350025P. R. China
- The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian ProvinceMengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhou350025P. R. China
| | - Aixian Zheng
- The Liver Center of Fujian ProvinceFujian Medical UniversityFuzhou350025P. R. China
- The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian ProvinceMengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhou350025P. R. China
| | - Juan Li
- The Key Lab of Analysis and Detection Technology for Food Safety of the MOEFujian Provincial Key Laboratory of Analysis and Detection Technology for Food SafetyCollege of ChemistryFuzhou UniversityFuzhou350002P. R. China
| | - Ming Wu
- The Liver Center of Fujian ProvinceFujian Medical UniversityFuzhou350025P. R. China
- The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian ProvinceMengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhou350025P. R. China
| | - Zhixiong Cai
- The Liver Center of Fujian ProvinceFujian Medical UniversityFuzhou350025P. R. China
- The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian ProvinceMengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhou350025P. R. China
| | - Lingjie Wu
- The Liver Center of Fujian ProvinceFujian Medical UniversityFuzhou350025P. R. China
- The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian ProvinceMengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhou350025P. R. China
| | - Zuwu Wei
- The Liver Center of Fujian ProvinceFujian Medical UniversityFuzhou350025P. R. China
- The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian ProvinceMengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhou350025P. R. China
| | - Huanghao Yang
- The Key Lab of Analysis and Detection Technology for Food Safety of the MOEFujian Provincial Key Laboratory of Analysis and Detection Technology for Food SafetyCollege of ChemistryFuzhou UniversityFuzhou350002P. R. China
| | - Xiaolong Liu
- The Liver Center of Fujian ProvinceFujian Medical UniversityFuzhou350025P. R. China
- The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian ProvinceMengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhou350025P. R. China
| | - Jingfeng Liu
- The Liver Center of Fujian ProvinceFujian Medical UniversityFuzhou350025P. R. China
- The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian ProvinceMengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhou350025P. R. China
- Liver Disease CenterThe First Affiliated Hospital of Fujian Medical UniversityFuzhou350005P. R. China
| |
Collapse
|
23
|
Aptamers for CD Antigens: From Cell Profiling to Activity Modulation. MOLECULAR THERAPY-NUCLEIC ACIDS 2016; 6:29-44. [PMID: 28325295 PMCID: PMC5363458 DOI: 10.1016/j.omtn.2016.12.002] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/23/2016] [Revised: 12/02/2016] [Accepted: 12/02/2016] [Indexed: 01/01/2023]
Abstract
Nucleic acid-based aptamers are considered to be a promising alternative to antibodies because of their strong and specific binding to diverse targets, fast and inexpensive chemical synthesis, and easy labeling with a fluorescent dye or therapeutic agent. Cluster of differentiation (CD) proteins are among the most popular antigens for aptamers on the cell surface. These anti-CD aptamers could be used in cell biology and biomedicine, from simple cell phenotyping by flow cytometry or fluorescent microscopy to diagnosis and treatment of HIV/AIDS to cancer and immune therapies. The unique feature of aptamers is that they can act simultaneously as an agonist and antagonist of CD receptors depending on a degree of aptamer oligomerization. Aptamers can also deliver small interfering RNA to silence vital genes in CD-positive cells. In this review, we summarize nucleic acid sequences of anti-CD aptamers and their use, which have been validated in multiple studies.
Collapse
|
24
|
Zhou Z, Song J, Nie L, Chen X. Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy. Chem Soc Rev 2016; 45:6597-6626. [PMID: 27722328 PMCID: PMC5118097 DOI: 10.1039/c6cs00271d] [Citation(s) in RCA: 1195] [Impact Index Per Article: 149.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The reactive oxygen species (ROS)-mediated mechanism is the major cause underlying the efficacy of photodynamic therapy (PDT). The PDT procedure is based on the cascade of synergistic effects between light, a photosensitizer (PS) and oxygen, which greatly favors the spatiotemporal control of the treatment. This procedure has also evoked several unresolved challenges at different levels including (i) the limited penetration depth of light, which restricts traditional PDT to superficial tumours; (ii) oxygen reliance does not allow PDT treatment of hypoxic tumours; (iii) light can complicate the phototherapeutic outcomes because of the concurrent heat generation; (iv) specific delivery of PSs to sub-cellular organelles for exerting effective toxicity remains an issue; and (v) side effects from undesirable white-light activation and self-catalysation of traditional PSs. Recent advances in nanotechnology and nanomedicine have provided new opportunities to develop ROS-generating systems through photodynamic or non-photodynamic procedures while tackling the challenges of the current PDT approaches. In this review, we summarize the current status and discuss the possible opportunities for ROS generation for cancer therapy. We hope this review will spur pre-clinical research and clinical practice for ROS-mediated tumour treatments.
Collapse
Affiliation(s)
- Zijian Zhou
- Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen 361102, China. and Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20892, USA.
| | - Jibin Song
- Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20892, USA.
| | - Liming Nie
- Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen 361102, China.
| | - Xiaoyuan Chen
- Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20892, USA.
| |
Collapse
|
25
|
Bharathiraja S, Seo H, Manivasagan P, Santha Moorthy M, Park S, Oh J. In Vitro Photodynamic Effect of Phycocyanin against Breast Cancer Cells. Molecules 2016; 21:molecules21111470. [PMID: 27827890 PMCID: PMC6273603 DOI: 10.3390/molecules21111470] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2016] [Accepted: 10/01/2016] [Indexed: 01/27/2023] Open
Abstract
C-phycocyanin, a natural blue-colored pigment-protein complex was explored as a novel photosensitizer for use in low-level laser therapy under 625-nm laser illumination. C-phycocyanin produced singlet oxygen radicals and the level of reactive oxygen species (ROS) were raised in extended time of treatment. It did not exhibit any visible toxic effect in the absence of light. Under 625-nm laser irradiation, c-phycocyanin generated cytotoxic stress through ROS induction, which killed MDA-MB-231 breast cancer cells depending on concentrations. Different fluorescent staining of laser-treated cells explored apoptotic cell death characteristics like the shrinking of cells, cytoplasmic condensation, nuclei cleavage, and the formation of apoptotic bodies. In conclusion, phycocyanin is a non-toxic fluorescent pigment that can be used in low-level light therapy.
Collapse
Affiliation(s)
| | - Hansu Seo
- Department of Biomedical Engineering and Center for Marine-Integrated Biotechnology (BK21 Plus), Pukyong National University, Busan 608-737, Korea.
| | | | | | - Suhyun Park
- Department of Biomedical Engineering, University of Texas at Austin, Austin, TX 78712, USA.
| | - Jungwan Oh
- Marine-Integrated Bionics Research Center, Pukyong National University, Busan 608-737, Korea.
- Department of Biomedical Engineering and Center for Marine-Integrated Biotechnology (BK21 Plus), Pukyong National University, Busan 608-737, Korea.
| |
Collapse
|
26
|
Abstract
This chapter focuses on the selection of RNA aptamers, which bind to specific cell surface components and thus can be internalized receptor mediated. Such aptamers discriminate between different tissues, e.g., detect malignant cells, and target them or induce apoptosis through drug internalization. However, before starting the selection process the choice of an ideal target can be challenging. To give an example for the selection of cell specific aptamers, we here used the interleukin-6 receptor (IL-6R) as a target, which is presented on hepatocytes, neutrophils, monocytes, and macrophages.
Collapse
Affiliation(s)
- Katharina Berg
- Chemistry Department, Institute for Biochemistry and Molecular Biology, MIN-Faculty, Hamburg University, Martin-Luther-King-Platz 6, 22391, Hamburg, Germany
| | - Eileen Magbanua
- Chemistry Department, Institute for Biochemistry and Molecular Biology, MIN-Faculty, Hamburg University, Martin-Luther-King-Platz 6, 22391, Hamburg, Germany
| | - Ulrich Hahn
- Chemistry Department, Institute for Biochemistry and Molecular Biology, MIN-Faculty, Hamburg University, Martin-Luther-King-Platz 6, 22391, Hamburg, Germany.
| |
Collapse
|
27
|
Szameit K, Berg K, Kruspe S, Valentini E, Magbanua E, Kwiatkowski M, Chauvot de Beauchêne I, Krichel B, Schamoni K, Uetrecht C, Svergun DI, Schlüter H, Zacharias M, Hahn U. Structure and target interaction of a G-quadruplex RNA-aptamer. RNA Biol 2016; 13:973-987. [PMID: 27471797 DOI: 10.1080/15476286.2016.1212151] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
G-quadruplexes have recently moved into focus of research in nucleic acids, thereby evolving in scientific significance from exceptional secondary structure motifs to complex modulators of gene regulation. Aptamers (nucleic acid based ligands with recognition properties for a specific target) that form Gquadruplexes may have particular potential for therapeutic applications as they combine the characteristics of specific targeting and Gquadruplex mediated stability and regulation. We have investigated the structure and target interaction properties of one such aptamer: AIR-3 and its truncated form AIR-3A. These RNA aptamers are specific for human interleukin-6 receptor (hIL-6R), a key player in inflammatory diseases and cancer, and have recently been exploited for in vitro drug delivery studies. With the aim to resolve the RNA structure, global shape, RNA:protein interaction site and binding stoichiometry, we now investigated AIR-3 and AIR-3A by different methods including RNA structure probing, Small Angle X-ray scattering and microscale thermophoresis. Our findings suggest a broader spectrum of folding species than assumed so far and remarkable tolerance toward different modifications. Mass spectrometry based binding site analysis, supported by molecular modeling and docking studies propose a general Gquadruplex affinity for the target molecule hIL-6R.
Collapse
Affiliation(s)
- Kristina Szameit
- a Institute for Biochemistry and Molecular Biology, Department of Chemistry , University of Hamburg , Hamburg , Germany
| | - Katharina Berg
- a Institute for Biochemistry and Molecular Biology, Department of Chemistry , University of Hamburg , Hamburg , Germany
| | - Sven Kruspe
- a Institute for Biochemistry and Molecular Biology, Department of Chemistry , University of Hamburg , Hamburg , Germany
| | - Erica Valentini
- b European Molecular Biology Laboratory, Hamburg Unit , Hamburg , Germany
| | - Eileen Magbanua
- a Institute for Biochemistry and Molecular Biology, Department of Chemistry , University of Hamburg , Hamburg , Germany
| | - Marcel Kwiatkowski
- c University Medical Center Hamburg-Eppendorf , Department of Clinical Chemistry , Hamburg , Germany
| | | | - Boris Krichel
- e Heinrich Pette Institute, Leibniz Institute for Experimental Virology , Hamburg , Germany
| | - Kira Schamoni
- e Heinrich Pette Institute, Leibniz Institute for Experimental Virology , Hamburg , Germany
| | - Charlotte Uetrecht
- e Heinrich Pette Institute, Leibniz Institute for Experimental Virology , Hamburg , Germany.,f European XFEL GmbH , Hamburg , Germany
| | - Dmitri I Svergun
- b European Molecular Biology Laboratory, Hamburg Unit , Hamburg , Germany
| | - Hartmut Schlüter
- c University Medical Center Hamburg-Eppendorf , Department of Clinical Chemistry , Hamburg , Germany
| | - Martin Zacharias
- d Physics Department , Technical University Munich , Garching , Germany
| | - Ulrich Hahn
- a Institute for Biochemistry and Molecular Biology, Department of Chemistry , University of Hamburg , Hamburg , Germany
| |
Collapse
|
28
|
Abstract
The unique properties of nucleic acid aptamers and their suitability to therapeutic applications have attracted the attention of researchers for more than 2 decades. Aptamers exhibit significant advantages relative to antibody-based therapeutics and can serve dual roles as either the therapeutic agent itself or a targeting modality. Despite this intense research interest, aptamers have been slow to reach the clinic, partly due to practical limitations that can be overcome by rational chemical modifications and ingenious aptamer selection approaches. This review highlights the latest efforts to use aptamers in therapeutic applications, the key properties of aptamers that can be exploited, the aptamers that are currently in clinical trials, as well as speculation on the future of aptamers in the field of nanomedicine.
Collapse
Affiliation(s)
- Christopher M C Mattice
- Department of Chemistry, Carleton University, 1125 Colonel By Drive, Ottawa, ON, K1S 5B6, Canada
| | | |
Collapse
|
29
|
Berg K, Lange T, Mittelberger F, Schumacher U, Hahn U. Selection and Characterization of an α6β4 Integrin blocking DNA Aptamer. MOLECULAR THERAPY. NUCLEIC ACIDS 2016; 5:e294. [PMID: 26978578 PMCID: PMC5014452 DOI: 10.1038/mtna.2016.10] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/21/2015] [Accepted: 01/21/2016] [Indexed: 12/28/2022]
Abstract
The heterodimeric laminin receptor α6β4 integrin plays a central role in the promotion of tumor cell growth, invasion, and organotropic metastasis. As an overproduction of the integrin is often linked to a poor prognosis, the inhibition of integrin α6β4 binding to laminin is of high therapeutical interest. Here, we report on the combination of a cell-systematic evolution of ligands by exponential enrichment and a bead-based selection resulting in the first aptamer inhibiting the interaction between α6β4 integrin and laminin-332. This Integrin α6β4-specific DNA Aptamer (IDA) inhibits the adhesion of prostate cancer cells (PC-3) to laminin-332 with an IC50 value of 149 nmol/l. The Kd value concerning the aptamer's interaction with PC-3 cells amounts to 137 nmol/l. Further characterization showed specificity to α6 integrins and a half-life in murine blood plasma of 6 hours. Two truncated versions of the aptamer retained their binding capacity, but lost their ability to inhibit the interaction between laminin-332 and PC-3 cells. Confocal laser scanning microscope studies revealed that the aptamer was internalized into PC-3-cells. Therefore, in addition to the adhesion-blocking function of this aptamer, IDA could also be applied for the delivery of siRNA, microRNA or toxins to cancer cells presenting the integrin α6β4.
Collapse
Affiliation(s)
- Katharina Berg
- MIN-Faculty, Chemistry Department, Institute for Biochemistry and Molecular Biology, University of Hamburg, Hamburg, Germany
| | - Tobias Lange
- University Medical Center Hamburg-Eppendorf, University Cancer Center, Institute of Anatomy and Experimental Morphology, Hamburg, Germany
| | - Florian Mittelberger
- MIN-Faculty, Chemistry Department, Institute for Biochemistry and Molecular Biology, University of Hamburg, Hamburg, Germany
| | - Udo Schumacher
- University Medical Center Hamburg-Eppendorf, University Cancer Center, Institute of Anatomy and Experimental Morphology, Hamburg, Germany
| | - Ulrich Hahn
- MIN-Faculty, Chemistry Department, Institute for Biochemistry and Molecular Biology, University of Hamburg, Hamburg, Germany
| |
Collapse
|
30
|
Yuan A, Laing B, Hu Y, Ming X. Direct oligonucleotide-photosensitizer conjugates for photochemical delivery of antisense oligonucleotides. Chem Commun (Camb) 2015; 51:6678-80. [PMID: 25786195 DOI: 10.1039/c5cc00573f] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Activation of photosensitizers in endosomes enables release of therapeutic macromolecules into the cytosol of the target cells for pharmacological actions. In this study, we demonstrate that direct conjugation of photosensitizers to oligonucleotides (ONs) allows spatial and temporal co-localization of the two modalities in the target cells, and thus leads to superior functional delivery of ONs. Further, light-activated delivery of an anticancer ON caused cancer cell killing via modulation of an oncogene and photodynamic therapy.
Collapse
Affiliation(s)
- Ahu Yuan
- Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.
| | | | | | | |
Collapse
|
31
|
Hirota M, Murakami I, Ishikawa Y, Suzuki T, Sumida SI, Ibaragi S, Kasai H, Horai N, Drolet DW, Gupta S, Janjic N, Schneider DJ. Chemically Modified Interleukin-6 Aptamer Inhibits Development of Collagen-Induced Arthritis in Cynomolgus Monkeys. Nucleic Acid Ther 2015; 26:10-9. [PMID: 26579954 PMCID: PMC4753578 DOI: 10.1089/nat.2015.0567] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Interleukin-6 (IL-6) is a potent mediator of inflammatory and immune responses, and a validated target for therapeutic intervention of inflammatory diseases. Previous studies have shown that SL1026, a slow off-rate modified aptamer (SOMAmer) antagonist of IL-6, neutralizes IL-6 signaling in vitro. In the present study, we show that SL1026 delays the onset and reduces the severity of rheumatoid symptoms in a collagen-induced arthritis model in cynomolgus monkeys. SL1026 (1 and 10 mg/kg), administered q.i.d., delayed the progression of arthritis and the concomitant increase in serum IL-6 levels compared to the untreated control group. Furthermore, SL1026 inhibited IL-6-induced STAT3 phosphorylation ex vivo in T lymphocytes from human blood and IL-6-induced C-reactive protein and serum amyloid A production in human primary hepatocytes. Importantly, SOMAmer treatment did not elicit an immune response, as evidenced by the absence of anti-SOMAmer antibodies in plasma of treated monkeys. These results demonstrate that SOMAmer antagonists of IL-6 may be attractive agents for the treatment of IL-6-mediated diseases, including rheumatoid arthritis.
Collapse
Affiliation(s)
- Masao Hirota
- 1 Otsuka Pharmaceutical Co., Ltd. , Tokushima, Japan
| | - Ikuo Murakami
- 1 Otsuka Pharmaceutical Co., Ltd. , Tokushima, Japan
| | | | - Tomoki Suzuki
- 1 Otsuka Pharmaceutical Co., Ltd. , Tokushima, Japan
| | | | | | - Hayato Kasai
- 2 Shin Nippon Biomedical Laboratories, Ltd. , Drug Safety Research Laboratories, Kagoshima, Japan
| | - Naoto Horai
- 2 Shin Nippon Biomedical Laboratories, Ltd. , Drug Safety Research Laboratories, Kagoshima, Japan
| | | | | | | | | |
Collapse
|
32
|
Lee JM, Oh KT, Youn YS, Lee ES. Highly enhanced phototoxicity of chlorin e6-conjugated poly(β-cyclodextrin) with gas forming capacity at an acidic tumor extracellular pH and its in vitro
evaluation. POLYM ADVAN TECHNOL 2015. [DOI: 10.1002/pat.3612] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Jae Min Lee
- Department of Biotechnology; The Catholic University of Korea; 43-1 Yeokgok 2-dong, Wonmi-gu Bucheon Gyeonggi-do 420-743 Republic of Korea
| | - Kyung Taek Oh
- College of Pharmacy; Chung-Ang University; 221 Heukseok dong, Dongjak-gu Seoul 155-756 Republic of Korea
| | - Yu Seok Youn
- School of Pharmacy; Sungkyunkwan University; 300 Chonchon-dong, Jangan-ku Suwon Gyeonggi-do 440-746 Republic of Korea
| | - Eun Seong Lee
- Department of Biotechnology; The Catholic University of Korea; 43-1 Yeokgok 2-dong, Wonmi-gu Bucheon Gyeonggi-do 420-743 Republic of Korea
| |
Collapse
|
33
|
Abstract
Western medicine often aims to specifically treat diseased tissues or organs. However, the majority of current therapeutics failed to do so owing to their limited selectivity and the consequent "off-target" side effects. Targeted therapy aims to enhance the selectivity of therapeutic effects and reduce adverse side effects. One approach toward this goal is to utilize disease-specific ligands to guide the delivery of less-specific therapeutics, such that the therapeutic effects can be guided specifically to diseased tissues or organs. Among these ligands, aptamers, also known as chemical antibodies, have emerged over the past decades as a novel class of targeting ligands that are capable of specific binding to disease biomarkers. Compared with other types of targeting ligands, aptamers have an array of unique advantageous features, which make them promising for developing aptamer-drug conjugates (ApDCs) for targeted therapy. In this Review, we will discuss ApDCs for targeted drug delivery in chemotherapy, gene therapy, immunotherapy, photodynamic therapy, and photothermal therapy, primarily of cancer.
Collapse
Affiliation(s)
- Guizhi Zhu
- Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health , Bethesda, Maryland 20892, United States
| | - Gang Niu
- Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health , Bethesda, Maryland 20892, United States
| | - Xiaoyuan Chen
- Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health , Bethesda, Maryland 20892, United States
| |
Collapse
|
34
|
McConnell EM, Holahan MR, DeRosa MC. Aptamers as promising molecular recognition elements for diagnostics and therapeutics in the central nervous system. Nucleic Acid Ther 2015; 24:388-404. [PMID: 25296265 DOI: 10.1089/nat.2014.0492] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
Oligonucleotide aptamers are short, synthetic, single-stranded DNA or RNA able to recognize and bind to a multitude of targets ranging from small molecules to cells. Aptamers have emerged as valuable tools for fundamental research, clinical diagnosis, and therapy. Due to their small size, strong target affinity, lack of immunogenicity, and ease of chemical modification, aptamers are an attractive alternative to other molecular recognition elements, such as antibodies. Although it is a challenging environment, the central nervous system and related molecular targets present an exciting potential area for aptamer research. Aptamers hold promise for targeted drug delivery, diagnostics, and therapeutics. Here we review recent advances in aptamer research for neurotransmitter and neurotoxin targets, demyelinating disease and spinal cord injury, cerebrovascular disorders, pathologies related to protein aggregation (Alzheimer's, Parkinson's, and prions), brain cancer (glioblastomas and gliomas), and regulation of receptor function. Challenges and limitations posed by the blood brain barrier are described. Future perspectives for the application of aptamers to the central nervous system are also discussed.
Collapse
Affiliation(s)
- Erin M McConnell
- 1 Department of Chemistry, Carleton University , Ottawa, Ontario, Canada
| | | | | |
Collapse
|
35
|
Benedetto G, Hamp TJ, Wesselman PJ, Richardson C. Identification of epithelial ovarian tumor-specific aptamers. Nucleic Acid Ther 2015; 25:162-72. [PMID: 25894736 DOI: 10.1089/nat.2014.0522] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Ovarian cancer is often diagnosed in late stages with few treatment options and poor long-term prognosis. New clinical tools for early detection of ovarian malignancies will significantly help reduce mortality and improve current long-term survival rates. The objective of this work was to identify ovarian tumor-specific single-stranded DNA aptamers that bind to malignant ovarian tumor cells and internalize with high affinity and specificity. Aptamers can identify unique tumor biomarkers, can aid in early detection and diagnosis of neoplastic disorders, and can be functionalized by conjugation to small molecules. To identify aptamers from random single-stranded DNA pools (60 bases long), we used whole Cell-SELEX (systematic evolution of ligands by exponential enrichment) to enrich and isolate tumor-specific aptamers that bind to tumor-specific receptors in their native state on the cell surface. Next-Generation sequencing identified seven novel aptamers and detailed analyses of three are described. Aptamers bound to, and were internalized by, target Caov-3 cell populations, but not nontarget nonmalignant ovarian epithelial HOSE 6-3 cells or multiple other epithelial tumor cell lines. Furthermore, aptamers showed unique binding affinities with apparent dissociation constants (Kd) measuring in the submicromolar range supporting their physiological relevance and potential use in clinical applications.
Collapse
Affiliation(s)
- Gregory Benedetto
- 1Department of Biological Sciences, University of North Carolina Charlotte, Charlotte, North Carolina
| | - Timothy J Hamp
- 1Department of Biological Sciences, University of North Carolina Charlotte, Charlotte, North Carolina.,2College of Computing and Informatics, University of North Carolina Charlotte, Charlotte, North Carolina
| | - Peter J Wesselman
- 1Department of Biological Sciences, University of North Carolina Charlotte, Charlotte, North Carolina
| | - Christine Richardson
- 1Department of Biological Sciences, University of North Carolina Charlotte, Charlotte, North Carolina
| |
Collapse
|
36
|
|
37
|
Tang CY, Liao YH, Tan GS, Wang XM, Lu GH, Yang YH. Targeted photosensitizer nanoconjugates based on human serum albumin selectively kill tumor cells upon photo-irradiation. RSC Adv 2015. [DOI: 10.1039/c5ra05251c] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
Small and non-toxic nanoconjugates RGD–HSA–Ce6 could provide targeted and effective photodynamic therapy of tumor cells.
Collapse
Affiliation(s)
- Cheng-Yi Tang
- State Key Laboratory of Pharmaceutical Biotechnology
- NJU-NJFU Joint Institute of Plant Molecular Biology
- School of Life Sciences
- Nanjing University
- Nanjing 210093
| | - Yong-hui Liao
- State Key Laboratory of Pharmaceutical Biotechnology
- NJU-NJFU Joint Institute of Plant Molecular Biology
- School of Life Sciences
- Nanjing University
- Nanjing 210093
| | - Guo-Sheng Tan
- State Key Laboratory of Pharmaceutical Biotechnology
- NJU-NJFU Joint Institute of Plant Molecular Biology
- School of Life Sciences
- Nanjing University
- Nanjing 210093
| | - Xiao-Ming Wang
- State Key Laboratory of Pharmaceutical Biotechnology
- NJU-NJFU Joint Institute of Plant Molecular Biology
- School of Life Sciences
- Nanjing University
- Nanjing 210093
| | - Gui-Hua Lu
- State Key Laboratory of Pharmaceutical Biotechnology
- NJU-NJFU Joint Institute of Plant Molecular Biology
- School of Life Sciences
- Nanjing University
- Nanjing 210093
| | - Yong-Hua Yang
- State Key Laboratory of Pharmaceutical Biotechnology
- NJU-NJFU Joint Institute of Plant Molecular Biology
- School of Life Sciences
- Nanjing University
- Nanjing 210093
| |
Collapse
|
38
|
Wiraja C, Yeo D, Lio D, Labanieh L, Lu M, Zhao W, Xu C. Aptamer technology for tracking cells' status & function. MOLECULAR AND CELLULAR THERAPIES 2014; 2:33. [PMID: 26056599 PMCID: PMC4452066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Figures] [Subscribe] [Scholar Register] [Received: 08/15/2014] [Accepted: 10/16/2014] [Indexed: 11/21/2023]
Abstract
In fields such as cancer biology and regenerative medicine, obtaining information regarding cell bio-distribution, tropism, status, and other cellular functions are highly desired. Understanding cancer behaviors including metastasis is important for developing effective cancer treatments, while assessing the fate of therapeutic cells following implantation is critical to validate the efficacy and efficiency of the therapy. For visualization purposes with medical imaging modalities (e.g. magnetic resonance imaging), cells can be labeled with contrast agents (e.g. iron-oxide nanoparticles), which allows their identification from the surrounding environment. Despite the success of revealing cell biodistribution in vivo, most of the existing agents do not provide information about the status and functions of cells following transplantation. The emergence of aptamers, single-stranded RNA or DNA oligonucleotides of 15 to 60 bases in length, is a promising solution to address this need. When aptamers bind specifically to their cognate molecules, they undergo conformational changes which can be transduced into a change of imaging contrast (e.g. optical, magnetic resonance). Thus by monitoring this signal change, researchers can obtain information about the expression of the target molecules (e.g. mRNA, surface markers, cell metabolites), which offer clues regarding cell status/function in a non-invasive manner. In this review, we summarize recent efforts to utilize aptamers as biosensors for monitoring the status and function of transplanted cells. We focus on cancer cell tracking for cancer study, stem cell tracking for regenerative medicine, and immune cell (e.g. dendritic cells) tracking for immune therapy.
Collapse
Affiliation(s)
- Christian Wiraja
- />Division of Bioengineering, School of Chemical and Biomedical Engineering, Nanyang Technological University, 70 Nanyang Drive, Singapore, 637457 Singapore
| | - David Yeo
- />Division of Bioengineering, School of Chemical and Biomedical Engineering, Nanyang Technological University, 70 Nanyang Drive, Singapore, 637457 Singapore
| | - Daniel Lio
- />Division of Bioengineering, School of Chemical and Biomedical Engineering, Nanyang Technological University, 70 Nanyang Drive, Singapore, 637457 Singapore
| | - Louai Labanieh
- />Department of Pharmaceutical Sciences, Sue and Bill Gross Stem Cell Research Center, Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA 92697 USA
- />Department of Biomedical Engineering, Edwards Lifesciences Center for Advanced Cardiovascular Technology, University of California Irvine, Irvine, CA 92697 USA
| | - Mengrou Lu
- />Department of Pharmaceutical Sciences, Sue and Bill Gross Stem Cell Research Center, Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA 92697 USA
- />Department of Biomedical Engineering, Edwards Lifesciences Center for Advanced Cardiovascular Technology, University of California Irvine, Irvine, CA 92697 USA
| | - Weian Zhao
- />Department of Pharmaceutical Sciences, Sue and Bill Gross Stem Cell Research Center, Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA 92697 USA
- />Department of Biomedical Engineering, Edwards Lifesciences Center for Advanced Cardiovascular Technology, University of California Irvine, Irvine, CA 92697 USA
| | - Chenjie Xu
- />Division of Bioengineering, School of Chemical and Biomedical Engineering, Nanyang Technological University, 70 Nanyang Drive, Singapore, 637457 Singapore
| |
Collapse
|
39
|
Wiraja C, Yeo D, Lio D, Labanieh L, Lu M, Zhao W, Xu C. Aptamer technology for tracking cells' status & function. MOLECULAR AND CELLULAR THERAPIES 2014; 2:33. [PMID: 26056599 PMCID: PMC4452066 DOI: 10.1186/2052-8426-2-33] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/15/2014] [Accepted: 10/16/2014] [Indexed: 02/07/2023]
Abstract
In fields such as cancer biology and regenerative medicine, obtaining information regarding cell bio-distribution, tropism, status, and other cellular functions are highly desired. Understanding cancer behaviors including metastasis is important for developing effective cancer treatments, while assessing the fate of therapeutic cells following implantation is critical to validate the efficacy and efficiency of the therapy. For visualization purposes with medical imaging modalities (e.g. magnetic resonance imaging), cells can be labeled with contrast agents (e.g. iron-oxide nanoparticles), which allows their identification from the surrounding environment. Despite the success of revealing cell biodistribution in vivo, most of the existing agents do not provide information about the status and functions of cells following transplantation. The emergence of aptamers, single-stranded RNA or DNA oligonucleotides of 15 to 60 bases in length, is a promising solution to address this need. When aptamers bind specifically to their cognate molecules, they undergo conformational changes which can be transduced into a change of imaging contrast (e.g. optical, magnetic resonance). Thus by monitoring this signal change, researchers can obtain information about the expression of the target molecules (e.g. mRNA, surface markers, cell metabolites), which offer clues regarding cell status/function in a non-invasive manner. In this review, we summarize recent efforts to utilize aptamers as biosensors for monitoring the status and function of transplanted cells. We focus on cancer cell tracking for cancer study, stem cell tracking for regenerative medicine, and immune cell (e.g. dendritic cells) tracking for immune therapy.
Collapse
Affiliation(s)
- Christian Wiraja
- />Division of Bioengineering, School of Chemical and Biomedical Engineering, Nanyang Technological University, 70 Nanyang Drive, Singapore, 637457 Singapore
| | - David Yeo
- />Division of Bioengineering, School of Chemical and Biomedical Engineering, Nanyang Technological University, 70 Nanyang Drive, Singapore, 637457 Singapore
| | - Daniel Lio
- />Division of Bioengineering, School of Chemical and Biomedical Engineering, Nanyang Technological University, 70 Nanyang Drive, Singapore, 637457 Singapore
| | - Louai Labanieh
- />Department of Pharmaceutical Sciences, Sue and Bill Gross Stem Cell Research Center, Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA 92697 USA
- />Department of Biomedical Engineering, Edwards Lifesciences Center for Advanced Cardiovascular Technology, University of California Irvine, Irvine, CA 92697 USA
| | - Mengrou Lu
- />Department of Pharmaceutical Sciences, Sue and Bill Gross Stem Cell Research Center, Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA 92697 USA
- />Department of Biomedical Engineering, Edwards Lifesciences Center for Advanced Cardiovascular Technology, University of California Irvine, Irvine, CA 92697 USA
| | - Weian Zhao
- />Department of Pharmaceutical Sciences, Sue and Bill Gross Stem Cell Research Center, Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA 92697 USA
- />Department of Biomedical Engineering, Edwards Lifesciences Center for Advanced Cardiovascular Technology, University of California Irvine, Irvine, CA 92697 USA
| | - Chenjie Xu
- />Division of Bioengineering, School of Chemical and Biomedical Engineering, Nanyang Technological University, 70 Nanyang Drive, Singapore, 637457 Singapore
| |
Collapse
|
40
|
Affiliation(s)
- Marc S Weinberg
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA
- Antiviral Gene Therapy Research Unit, Department of Molecular Medicine and Haematology, School of Pathology, University of the Witwatersrand Medical School, Parktown, South Africa
| |
Collapse
|
41
|
Kruspe S, Hahn U. An aptamer intrinsically comprising 5-fluoro-2'-deoxyuridine for targeted chemotherapy. Angew Chem Int Ed Engl 2014; 53:10541-4. [PMID: 25145319 DOI: 10.1002/anie.201405778] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2014] [Indexed: 12/20/2022]
Abstract
An aptamer specifically binding the interleukin-6 receptor and intrinsically comprising multiple units of the nucleoside analogue 5-fluoro-2'-deoxyuridine can exert a cytostatic effect direcly on certain cells presenting the receptor. Thus the modified aptamer fulfils the requirements for active drug targeting in an unprecedented manner. It can easily be synthesized in a single enzymatic step and it binds to a cell surface receptor that is conveyed into the lysosome. Upon degradation of the aptamer by intracellular nucleases the active drug is released within the targeted cells exclusively. In this way the aptamer acts as a prodrug meeting two major prerequisites of a drug delivery system: specific cell targeting and the controlled release of the drug triggered by an endogenous stimulus.
Collapse
Affiliation(s)
- Sven Kruspe
- Institut für Biochemie und Molekularbiologie, Universität Hamburg, Martin-Luther-King Platz 6, 20146 Hamburg (Germany)
| | | |
Collapse
|
42
|
Kruspe S, Hahn U. Ein intrinsisch 5-Fluor-2′-desoxyuridin beinhaltendes Aptamer für die gezielte Chemotherapie. Angew Chem Int Ed Engl 2014. [DOI: 10.1002/ange.201405778] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
43
|
Kruspe S, Mittelberger F, Szameit K, Hahn U. Aptamers as drug delivery vehicles. ChemMedChem 2014; 9:1998-2011. [PMID: 25130604 DOI: 10.1002/cmdc.201402163] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2014] [Revised: 07/02/2014] [Indexed: 01/22/2023]
Abstract
The benefits of directed and selective therapy for systemic treatment are reasons for increased interest in exploiting aptamers for cell-specific drug delivery. Nucleic acid based pharmaceuticals represent an interesting and novel tool to counter human diseases. Combining inhibitory potential and cargo transfer upon internalization, nanocarriers as well as various therapeutics including siRNAs, chemotherapeutics, photosensitizers, or proteins can be imported via these synthetic nucleic acids. However, widespread clinical application is still hampered by obstacles that must be overcome. In this review, we give an overview of applications and recent advances in aptamer-mediated drug delivery. We also introduce prominent selection methods as well as useful approaches in choice of drug and conjugation method. We discuss the challenges that need to be considered and present strategies that have been applied to achieve intracellular delivery of effectors transported by readily internalized aptamers.
Collapse
Affiliation(s)
- Sven Kruspe
- Institut für Biochemie und Molekularbiologie, Universität Hamburg, Martin-Luther-King Platz 6, 20146 Hamburg (Germany)
| | | | | | | |
Collapse
|